The Phase III trial sponsored by UNICANCER aims to evaluate the efficacy of combined radiotherapy with cisplatin and fluorouracil versus radiotherapy alone in patients with advanced, nonresectable squamous cell carcinoma of the oropharynx or hypopharynx. Given the increasing incidence of head and neck cancers, particularly in the context of HPV-related cases, successful outcomes could position the combination therapy as a standard of care, potentially capturing significant market share in oncology. The competitive landscape includes existing therapies such as single-agent chemotherapy and alternative radiotherapy regimens. Diligence should focus on the trial's safety profile, overall survival rates, and quality of life assessments to gauge market readiness and reimbursement potential.